Our findings indicate a significant role of the CYP2D6 gene polymorphisms in predicting the reduction in anxiety disorders, interestingly without a clear influence on the reduction in depressive symptoms during duloxetine therapy among patients with MDD. This evidence concerns the gene CYP2D6 and major depressive disorder.